Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,473
Recruiting: 1,285
Ph III recruiting: 130
Growth YoY: +7.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,640)

clinicaltrialsPublishedShowing 1–50 of 3,460 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01087294	Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation	completed	Phase 1	85	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT02180711	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	active not recruiting	Phase 1 / Phase 2	113	Acerta Pharma BVINDUSTRY	3	Sep 28, 2026